Longeveron LLC (LGVN NASDAQ) stock market data APIs
$0.8163
-0.01(-1.2%)
as of May 28, 2026
Try our APIs with
free plan!
Longeveron LLC Financial Data Overview
Price chart is built with
Anychart
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Prev. Close
0.8163
Open
0.8029
High
0.8331
Low
0.7802
52 wk Range
0.475-1.8
Market Cap
25 749 K
Shares Outstanding
30 149 K
Revenue
1 216 K
EPS
-0.19
Beta
-0.321
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Longeveron LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Longeveron LLC data using free add-ons & libraries
Get Longeveron LLC Fundamental Data
Longeveron LLC Fundamental data includes:
- Net Revenue: 1 216 K
- EBITDA: -21 824 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: -0.1725
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Longeveron LLC News
New
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model
Earnings Call Insights: Longeveron (LGVN) Q1 2026 MANAGEMENT VIEW * “After I took on the role as CEO in February, we embarked on 2 immediate critical tasks, a comprehensive review of the company...
Longeveron Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Longeveron (NASDAQ:LGVN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings ca...
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is proje...
Longeveron Holds Constructive FDA Meeting; ELPIS II Topline Data Expected August 2026
(RTTNews) - Longeveron Inc. (LGVN) on Friday announced it held a constructive Type C meeting with the U.S. FDA regarding its ongoing Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic...
Get Longeveron LLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
